Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A, González-Cantero A, Khattri S, Muzy G, Malatestinic WN, Lampropoulou A, Feely M, See SK, Mert C, Blauvelt A. Armstrong A, et al. Among authors: mert c. Dermatol Ther (Heidelb). 2024 Apr;14(4):933-952. doi: 10.1007/s13555-024-01136-w. Epub 2024 Mar 23. Dermatol Ther (Heidelb). 2024. PMID: 38521874 Free PMC article.
Ixekizumab im Vergleich zu Fumarsäureestern und Methotrexat bei der Behandlung der Nagelpsoriasis bei Patienten mit mittelschwerer bis schwerer Psoriasis: Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis.
Augustin M, Mrowietz U, Willsmann-Theis D, Gerdes S, Fotiou K, Schuster C, Mert C, Holzkaemper T, Behrens F, Pinter A. Augustin M, et al. Among authors: mert c. J Dtsch Dermatol Ges. 2024 Feb;22(2):278-282. doi: 10.1111/ddg.15292_g. J Dtsch Dermatol Ges. 2024. PMID: 38361190 No abstract available.
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).
Piaserico S, Riedl E, Pavlovsky L, Vender RB, Mert C, Tangsirisap N, Haustrup N, Gallo G, Schuster C, Brunner PM. Piaserico S, et al. Among authors: mert c. Front Med (Lausanne). 2023 Jun 29;10:1185523. doi: 10.3389/fmed.2023.1185523. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37457564 Free PMC article.
Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey.
Augustin M, Costanzo A, Pink A, Seneschal J, Schuster C, Mert C, Guerreiro M, Tietz N, Grond S, De Bruin-Weller M. Augustin M, et al. Among authors: mert c. Acta Derm Venereol. 2022 Dec 7;102:adv00830. doi: 10.2340/actadv.v102.3932. Acta Derm Venereol. 2022. PMID: 36479885 Free PMC article.
Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain.
Artime E, Serra E, Mert C, Díaz-Cerezo S, Huete T, Hernández-Subirá I, Lledo-Bryant L, Sicras-Mainar A. Artime E, et al. Among authors: mert c. Actas Dermosifiliogr. 2023 Jan;114(1):T9-T18. doi: 10.1016/j.ad.2022.08.025. Epub 2022 Nov 8. Actas Dermosifiliogr. 2023. PMID: 36368579 Free article. English, Spanish.
Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain.
Artime E, Serra E, Mert C, Díaz-Cerezo S, Huete T, Hernández-Subirá I, Lledo-Bryant L, Sicras-Mainar A. Artime E, et al. Among authors: mert c. Actas Dermosifiliogr. 2023 Jan;114(1):9-18. doi: 10.1016/j.ad.2022.08.015. Epub 2022 Aug 27. Actas Dermosifiliogr. 2023. PMID: 36030827 Free article. English, Spanish.
21 results